211 related articles for article (PubMed ID: 31900919)
21. Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing.
Pflueger D; Terry S; Sboner A; Habegger L; Esgueva R; Lin PC; Svensson MA; Kitabayashi N; Moss BJ; MacDonald TY; Cao X; Barrette T; Tewari AK; Chee MS; Chinnaiyan AM; Rickman DS; Demichelis F; Gerstein MB; Rubin MA
Genome Res; 2011 Jan; 21(1):56-67. PubMed ID: 21036922
[TBL] [Abstract][Full Text] [Related]
22. Novel 5' fusion partners of ETV1 and ETV4 in prostate cancer.
Barros-Silva JD; Paulo P; Bakken AC; Cerveira N; Løvf M; Henrique R; Jerónimo C; Lothe RA; Skotheim RI; Teixeira MR
Neoplasia; 2013 Jul; 15(7):720-6. PubMed ID: 23814484
[TBL] [Abstract][Full Text] [Related]
23. Transcriptomes of Prostate Cancer with TMPRSS2:ERG and Other ETS Fusions.
Stopsack KH; Su XA; Vaselkiv JB; Graff RE; Ebot EM; Pettersson A; Lis RT; Fiorentino M; Loda M; Penney KL; Lotan TL; Mucci LA
Mol Cancer Res; 2023 Jan; 21(1):14-23. PubMed ID: 36125519
[TBL] [Abstract][Full Text] [Related]
24. [The progress of TMPRSS2-ETS gene fusions and their mechanism in prostate cancer].
Guo XQ; Gui YT; Cai ZM
Yi Chuan; 2011 Feb; 33(2):117-22. PubMed ID: 21377967
[TBL] [Abstract][Full Text] [Related]
25. Molecular profiling of ETS and non-ETS aberrations in prostate cancer patients from northern India.
Ateeq B; Kunju LP; Carskadon SL; Pandey SK; Singh G; Pradeep I; Tandon V; Singhai A; Goel A; Amit S; Agarwal A; Dinda AK; Seth A; Tsodikov A; Chinnaiyan AM; Palanisamy N
Prostate; 2015 Jul; 75(10):1051-62. PubMed ID: 25809148
[TBL] [Abstract][Full Text] [Related]
26. ETS rearrangements and prostate cancer initiation.
Carver BS; Tran J; Chen Z; Carracedo-Perez A; Alimonti A; Nardella C; Gopalan A; Scardino PT; Cordon-Cardo C; Gerald W; Pandolfi PP
Nature; 2009 Feb; 457(7231):E1; discussion E2-3. PubMed ID: 19212347
[TBL] [Abstract][Full Text] [Related]
27. FLI1 is a novel ETS transcription factor involved in gene fusions in prostate cancer.
Paulo P; Barros-Silva JD; Ribeiro FR; Ramalho-Carvalho J; Jerónimo C; Henrique R; Lind GE; Skotheim RI; Lothe RA; Teixeira MR
Genes Chromosomes Cancer; 2012 Mar; 51(3):240-9. PubMed ID: 22081504
[TBL] [Abstract][Full Text] [Related]
28. The Expression of Proto-Oncogene
Khosh Kish E; Choudhry M; Gamallat Y; Buharideen SM; D D; Bismar TA
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563163
[TBL] [Abstract][Full Text] [Related]
29. ETS factors in prostate cancer.
Qian C; Li D; Chen Y
Cancer Lett; 2022 Apr; 530():181-189. PubMed ID: 35033589
[TBL] [Abstract][Full Text] [Related]
30. ETS gene fusions in prostate cancer.
Clark JP; Cooper CS
Nat Rev Urol; 2009 Aug; 6(8):429-39. PubMed ID: 19657377
[TBL] [Abstract][Full Text] [Related]
31. Phosphorylation of the oncogenic transcription factor ERG in prostate cells dissociates polycomb repressive complex 2, allowing target gene activation.
Kedage V; Strittmatter BG; Dausinas PB; Hollenhorst PC
J Biol Chem; 2017 Oct; 292(42):17225-17235. PubMed ID: 28887309
[TBL] [Abstract][Full Text] [Related]
32. Modulation of androgen receptor DNA binding activity through direct interaction with the ETS transcription factor ERG.
Wasmuth EV; Hoover EA; Antar A; Klinge S; Chen Y; Sawyers CL
Proc Natl Acad Sci U S A; 2020 Apr; 117(15):8584-8592. PubMed ID: 32220959
[TBL] [Abstract][Full Text] [Related]
33. Androgen regulation of ETS gene fusion transcripts in prostate cancer.
Gasi D; Trapman J
Methods Mol Biol; 2011; 776():335-48. PubMed ID: 21796535
[TBL] [Abstract][Full Text] [Related]
34. ETS transcription factors: oncogenes and tumor suppressor genes as therapeutic targets for prostate cancer.
Turner DP; Watson DK
Expert Rev Anticancer Ther; 2008 Jan; 8(1):33-42. PubMed ID: 18095881
[TBL] [Abstract][Full Text] [Related]
35. Distinct genomic aberrations associated with ERG rearranged prostate cancer.
Demichelis F; Setlur SR; Beroukhim R; Perner S; Korbel JO; Lafargue CJ; Pflueger D; Pina C; Hofer MD; Sboner A; Svensson MA; Rickman DS; Urban A; Snyder M; Meyerson M; Lee C; Gerstein MB; Kuefer R; Rubin MA
Genes Chromosomes Cancer; 2009 Apr; 48(4):366-80. PubMed ID: 19156837
[TBL] [Abstract][Full Text] [Related]
36. Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer.
Winnes M; Lissbrant E; Damber JE; Stenman G
Oncol Rep; 2007 May; 17(5):1033-6. PubMed ID: 17390040
[TBL] [Abstract][Full Text] [Related]
37. TMPRSS2:ETS fusions and clinicopathologic characteristics of prostate cancer patients from Eastern China.
Dong J; Xiao L; Sheng L; Xu J; Sun ZQ
Asian Pac J Cancer Prev; 2014; 15(7):3099-103. PubMed ID: 24815454
[TBL] [Abstract][Full Text] [Related]
38. Wnt receptor Frizzled 8 is a target of ERG in prostate cancer.
Chakravarthi BVSK; Chandrashekar DS; Hodigere Balasubramanya SA; Robinson AD; Carskadon S; Rao U; Gordetsky J; Manne U; Netto GJ; Sudarshan S; Palanisamy N; Varambally S
Prostate; 2018 Dec; 78(16):1311-1320. PubMed ID: 30051493
[TBL] [Abstract][Full Text] [Related]
39. Specific and redundant activities of ETV1 and ETV4 in prostate cancer aggressiveness revealed by co-overexpression cellular contexts.
Mesquita D; Barros-Silva JD; Santos J; Skotheim RI; Lothe RA; Paulo P; Teixeira MR
Oncotarget; 2015 Mar; 6(7):5217-36. PubMed ID: 25595908
[TBL] [Abstract][Full Text] [Related]
40. Prostate cancer ETS rearrangements switch a cell migration gene expression program from RAS/ERK to PI3K/AKT regulation.
Selvaraj N; Budka JA; Ferris MW; Jerde TJ; Hollenhorst PC
Mol Cancer; 2014 Mar; 13():61. PubMed ID: 24642271
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
